larixyl acetate

TRPC6 inhibitor

Also Known As:

(4aS)-4-(3-acetoxy-3-methyl-4-penten-1-yl)-4a,8,8-trimethyl-3-methylenedecahydro-1-naphthalenyl acetate; 1-naphthalenepropanol, 4-(acetyloxy)-alpha-ethenyldecahydro-alpha,5,5,8a-tetramethyl-2-methylene-, acetate, (8aS)-

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chen, Kun: 1 article (04/2020)
2.	Hong, Jiang-Hao: 1 article (04/2020)
3.	Jia, Peng: 1 article (04/2020)
4.	Jin, Xiao-Hang: 1 article (04/2020)
5.	Liu, Fang-Fang: 1 article (04/2020)
6.	Meng, Fei-Yang: 1 article (04/2020)
7.	Shi, Juan: 1 article (04/2020)
8.	Wang, Jing: 1 article (04/2020)
9.	Zhang, Ting: 1 article (04/2020)
10.	Zhao, Ming: 1 article (04/2020)

Related Diseases

1.	Traumatic Brain Injuries (Traumatic Brain Injury) 01/31/2019 - "The TRPC6 inhibitor, larixyl acetate, is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction."
2.	Neuralgia (Stump Neuralgia) 04/16/2020 - "The analgesic action of larixyl acetate, a potent TRPC6 inhibitor, in rat neuropathic pain model induced by spared nerve injury."
3.	Hypoxia (Hypoxemia) 01/01/2016 - "In isolated mouse lungs, larix-6-yl monoacetate (CAS 4608-49-5; larixyl acetate; 5 µM) prevented acute hypoxia-induced vasoconstriction. "

Related Drugs and Biologics

1.	TRPC6 Cation Channel
2.	Analgesics (Analgesic Drugs)